Orasure Technologies (OSUR) AI Stock Analysis

• Market Cap: $225.96M
• Dividend Yield: N/A
• Average Volume (3M): 771.42K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.72
• Revenue Growth: -43.95%
• EPS Growth: -620.21%
• Country: US
• Employees: 501
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Instruments & Supplies
• EPS (TTM): -0.27
• Shares Outstanding: 71,733,530
• 10 Day Avg. Volume: 735,713
• 30 Day Avg. Volume: 771,421
• PEG Ratio: >-0.01
• Price to Book (P/B): 0.52
• Price to Sales (P/S): 1.55
• P/FCF Ratio: -3.34K
• Enterprise Value/Market Cap: 1.02
• Enterprise Value/Revenue: 2.00
• Enterprise Value/Gross Profit: 5.24
• Enterprise Value/Ebitda: -3.68
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): -0.76
• Revenue Forecast (FY): $118.95M

• Rating: 51 Neutral
• Price Target: $3.00 ▲(26.05% Upside)
• Action: Reiterated Date: 02/26/26
• Date: Action: Reiterated 02/26/26

The score is held back primarily by deteriorated financial performance (losses, sharp revenue contraction, and recent cash burn). The latest earnings call provides partial support via stabilization signals (improving gross margin outlook, strong cash/no debt, and product-catalyst pipeline), while technicals are neutral-to-slightly positive and valuation remains challenged due to negative earnings.

Positive Factors

Strong cash position & zero debt

A $199M cash balance with no debt provides a durable liquidity buffer to fund R&D, regulatory reviews, and commercialization efforts without immediate financing pressure. Coupled with active buybacks, this balance sheet flexibility supports multi-year product development and gives management optionality to absorb near-term cash burn while pursuing the H2 2026 ramp.

Near-term FDA product catalysts

Regulatory submissions for an OTC CT/NG molecular self-test and an at‑home urine collection device, if cleared, structurally expand access to decentralized STI testing and address a large TAM (> $1.5B). Successful approvals would diversify revenues away from lab-centric channels and create a sustainable growth vector through durable market expansion and new distribution models.

Manufacturing consolidation and margin leverage

Consolidating manufacturing and internalizing most sample management volumes meaningfully increases fixed‑cost absorption potential. With operations currently underoccupied, any sustained volume recovery should yield durable gross‑margin expansion through higher capacity utilization and lower outsourcing costs, supporting margin sustainability as revenue scales.

Negative Factors

Sharp revenue decline and lost profitability

A steep decline in revenue and a shift from solid 2023 profits to multi-year losses indicate a structural erosion of scale. Reduced top‑line weakens the firm’s ability to cover fixed costs and maintain R&D and commercial investments, extending the timeline to sustainable margins and increasing sensitivity to execution on new product launches.

Negative operating cash flow and multi‑year burn risk

Negative operating cash flow and a multi‑year path to breakeven create persistent cash‑burn risk. Even with a large cash balance today, continued negative OCF forces reliance on either rapid commercial execution or external financing, limiting long‑term strategic flexibility and increasing downside if regulatory or market ramps slip.

Regulatory and funding execution risk

Revenue recovery depends on timely FDA approvals and stable international public‑health funding. Regulatory review delays or recurring funding disruptions materially postpone the expected H2 2026 ramp, prolong underutilized capacity, and jeopardize the company’s ability to convert product catalysts into sustained revenue and margin improvements.

Orasure Technologies Business Overview & Revenue Model

Company Description

OraSure Technologies, Inc. is a leader in the field of oral fluid diagnostics and medical devices, primarily focusing on the development and sale of products for the detection of infectious diseases and for drug testing. The company operates in two main sectors: the infectious disease testing market and the substance abuse testing market. Its core products include rapid diagnostic tests for HIV, HCV, and other infectious diseases, as well as oral fluid collection devices used for drug testing and other applications.

How the Company Makes Money

OraSure Technologies generates revenue primarily through the sale of its diagnostic products and testing services. Key revenue streams include sales from its OraQuick rapid HIV tests, which are used in various healthcare settings, and its testing solutions for hepatitis C. The company also earns revenue from its collection devices, which are utilized in drug testing programs. Significant partnerships with governmental health organizations, pharmaceutical companies, and healthcare providers enhance its market reach and drive sales. Additionally, OraSure's involvement in research and development grants and collaborations further contributes to its earnings, positioning it as a vital player in public health initiatives.

Orasure Technologies Financial Statement Overview

Summary

Financials have weakened materially: profitability flipped from strong in 2023 to losses in 2024–2025, revenue contracted sharply, and cash flow turned negative in 2025. Low historical leverage helps, but the latest period signals elevated operating and cash-burn risk.

Income Statement

Profitability and growth have deteriorated sharply. The company went from solid profitability in 2023 (positive net margin ~13%) to losses in 2024 (net margin ~-10%) and very weak results in 2025, with revenue collapsing to a fraction of the prior year and margins deeply negative. While gross margin has generally been mid-40% historically, the recent step-down in scale has overwhelmed the cost structure and driven heavy operating losses.

Balance Sheet

Leverage appears low in recent annual periods (debt-to-equity ~3–4% in 2022–2024), which is a key stabilizer. However, the latest 2025 figures show stockholders’ equity reported at 0 alongside zero debt, which raises a data-quality or balance-sheet stress flag and reduces confidence in balance-sheet strength for the most recent period. Earlier years show a sizable equity base and moderate asset levels, but returns turned negative again in 2024.

Cash Flow

Cash generation has become inconsistent and recently negative. After very strong operating and free cash flow in 2023, cash flow weakened materially in 2024 (positive but far lower) and turned negative in 2025 (both operating cash flow and free cash flow). The negative 2025 cash flow alongside large accounting losses suggests continued cash burn risk if conditions don’t stabilize.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	115.02M	185.83M	405.47M	387.48M	233.67M
Gross Profit	48.20M	76.23M	179.42M	148.44M	117.60M
EBITDA	-56.74M	-9.73M	73.98M	8.76M	9.00K
Net Income	-68.73M	-19.50M	53.66M	-17.13M	-23.00M
Balance Sheet
Total Assets	403.17M	479.66M	482.85M	444.18M	460.99M
Cash, Cash Equivalents and Short-Term Investments	199.28K	267.76M	290.41M	110.85M	153.04M
Total Debt	0.00	14.60M	13.50M	12.55M	12.27M
Total Liabilities	62.34M	69.32M	52.17M	79.75M	80.46M
Stockholders Equity	340.83M	410.34M	430.67M	364.43M	380.53M
Cash Flow
Free Cash Flow	-53.22K	23.58M	131.28M	-111.11M	-83.50M
Operating Cash Flow	-49.02K	27.37M	141.58M	-47.20M	-35.38M
Investing Cash Flow	-6.81K	-39.03M	66.15M	21.09M	-5.50M
Financing Cash Flow	-16.94K	-4.18M	-3.02M	-3.83M	-2.82M

Orasure Technologies Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 2.38
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For OSUR, the sentiment is Positive. The current price of 2.38 is below the 20-day moving average (MA) of 2.83, below the 50-day MA of 2.67, and below the 200-day MA of 2.84, indicating a bullish trend. The MACD of 0.08 indicates Negative momentum. The RSI at 69.96 is Neutral, neither overbought nor oversold. The STOCH value of 78.25 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for OSUR.

Orasure Technologies Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
INFU	74 Outperform	$178.35M	27.81	11.54%	―	6.23%	283.88%
UTMD	71 Outperform	$213.40M	19.12	9.59%	2.15%	-12.35%	-17.20%
STXS	62 Neutral	$201.58M	-7.68	-170.24%	―	19.61%	-3.42%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
OSUR	51 Neutral	$225.96M	-3.37	-15.30%	―	-43.95%	-620.21%
SMTI	42 Neutral	$182.64M	-4.71	-27.19%	―	30.55%	-340.19%

Orasure Technologies Corporate Events

OraSure Highlights 2025 Results and 2026 Growth Outlook

On February 25, 2026, OraSure reported fourth-quarter 2025 net revenue of $26.8 million, in line with expectations and above the midpoint of guidance, though down 29% year over year as total 2025 revenue fell 38% to $115.0 million, reflecting steep declines in COVID-19, risk assessment testing, and molecular services. Management highlighted improved funding stability in key segments, stronger gross margins, a solid balance sheet, and an active $40 million share repurchase program, and said the business is positioned to return to growth in 2026 as it prepares U.S. launches of a rapid molecular self-test for chlamydia and gonorrhea and the Colli-Pee at-home urine collection device for sexually transmitted infections.

The most recent analyst rating on (OSUR) stock is a Hold with a $3.00 price target. To see the full list of analyst forecasts on Orasure Technologies stock, see the OSUR Stock Forecast page.

OraSure Seeks FDA Clearance for New STI Tests

On January 5, 2026, OraSure Technologies reported that at the end of 2025 it submitted two applications to the U.S. Food and Drug Administration seeking clearance for a rapid molecular self-test for Chlamydia trachomatis and Neisseria gonorrhoeae and for its Colli-Pee at-home urine collection device for sexually transmitted infections. The CT/NG self-test, built on the Sherlock molecular diagnostics platform, is designed as a disposable, over-the-counter product that delivers results in about 30 minutes from a self-collected swab without requiring an electrical connection, targeting a U.S. testing market the company estimates exceeds $1.5 billion, which is currently dominated by centralized laboratory testing. The Colli-Pee device, already available for research use only, is intended to support private, convenient at-home urine collection for multiple STI indications in collaboration with a leading diagnostics platform provider, and FDA clearance would expand access to STI testing and reinforce OraSure’s positioning in decentralized diagnostics and novel sample collection technologies.

The most recent analyst rating on (OSUR) stock is a Hold with a $2.50 price target. To see the full list of analyst forecasts on Orasure Technologies stock, see the OSUR Stock Forecast page.

OraSure Technologies Executives Adopt Stock Trading Plans

On December 1, 2025, OraSure Technologies announced that its President and CEO, Carrie Eglinton Manner, and CFO, Kenneth McGrath, adopted Rule 10b5-1 trading plans for purchasing the company’s common stock. These plans are part of the company’s ongoing share repurchase program and are structured to comply with the Securities Exchange Act of 1934 and the company’s Insider Trading Policy. The trading plans allow each executive to potentially purchase up to $165,000 of shares within six months after a specified commencement date, with trading beginning after a cooling-off period. This move is expected to align the interests of the executives with those of the shareholders, potentially impacting the company’s market perception and stakeholder confidence.

The most recent analyst rating on (OSUR) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Orasure Technologies stock, see the OSUR Stock Forecast page.